Friday 23rd February 2024 |
Text too small? |
For the third quarter ending 31 Dec 2023, Blis Technologies Limited (Blis) delivered revenue growth of 10% on the same period last year and a positive EBITDA result of $0.3m (unaudited).
Revenue growth came from a 12% increase in B2B revenue and a stronger than expected result for New Zealand and Amazon.
“Momentum continues to build around the successful execution of the refocused strategic plan. This has involved amongst other activities, working closely with business partners to sell more Blis product profitably into B2C and B2B channels.” said Scott Johnson, CEO.
Based on the latest customer sales forecasts and market feedback, guidance is for full year revenue to be about $11.0m, with EBITDA in the range of breakeven to $0.3m. This marks a return to profitability for the company.
Ends
For further information, please contact:
Scott Johnson
CEO
+64 21 488 831
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.
No comments yet
EXPRESSION OF INTEREST IN THE SUPPLY OF MEREENIE GAS
IPL - FY24 Annual Results
CEN - Contact to revisit Wairākei development options
May 17th Morning Report
PaySauce to announce full year results on 22 May 2024
BGP - Results of Briscoe Group Limited Annual Shareholder Meeting
Judith Swales to leave Fonterra
Fonterra announces step-change in strategic direction
USX Trading Results 15th May
Devon Funds Morning Note - 15 May 2024